Medicine
Volume 35, Issue 11 , Pages 590-591, November 2007

Antidiabetic drugs

W Stephen Waring FRCPE PhD is a Consultant Toxicologist at the Royal Infirmary of Edinburgh, and honorary Senior Lecturer in Clinical Pharmacology at the University of Edinburgh. He has previously worked within the pharmaceutical industry, and research interests include early drug development, assessment of drug safety, and clinical aspects of poisoning. Conflicts of interest: none declared

Abstract 

Over recent years, there has been rapid expansion of different classes of antihyperglycaemic drugs. Each possesses a unique pharmacological mechanism of action and, correspondingly, they have diverse toxicological profiles. Antidiabetic drugs have the potential to exert severe toxic effects, and patients normally require urgent medical assessment and treatment.

Keywords: acarbose, antidiabetic, antihyperglycaemic, DPP-IV inhibitor, GLP-1, insulin, metformin, overdose, sulphonylureas, thiazolidinediones

To access this article, please choose from the options below

Login to an existing account or Register a new account.

  • Purchase this article for 31.50 USD (You must login/register to purchase this article)

    Online access for 24 hours. The PDF version can be downloaded as your permanent record.

  • Subscribe to this title

    Get unlimited online access to this article and all other articles in this title 24/7 for one year.

  • Claim access now

    For current subscribers with Society Membership or Account Number.

  • Visit SciVerse ScienceDirect to see if you have access via your institution.
 

PII: S1357-3039(07)00288-5

doi:10.1016/j.mpmed.2007.08.016

Medicine
Volume 35, Issue 11 , Pages 590-591, November 2007

Article Tools